Innate Pharma
IPHA
8 hedge funds and large institutions have $545K invested in Innate Pharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 0 closing their positions.
16% more capital invested
Capital invested by funds: $469K → $545K (+$76.1K)
0% more funds holding
Funds holding: 8 → 8 (0)
0% less ownership
Funds ownership: 0.3% → 0.29% (-0%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$19.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.99K |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
-$1.25K |
| 4 |
Barclays
London,
United Kingdom
|
-$232 |
IPHA Hedge Fund Activity: Q3 2024 in Review
8 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2024, worth a combined $545K — up 16% from $469K a quarter earlier.
Fund positioning in IPHA was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, adding an estimated $17.9K. The largest seller was Exchange Traded Concepts, cutting an estimated $19.6K.
- 8 institutional investors held Innate Pharma (IPHA) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $545K of Innate Pharma stock for Q3 2024, up 16% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q3 2024 and 0 closed out.
- The largest Innate Pharma buyer in Q3 2024 was UBS Group, an estimated $17.9K added.
- The largest Innate Pharma seller in Q3 2024 was Exchange Traded Concepts, an estimated $19.6K sold.
Based on aggregated 13F filings for Q3 2024.